Literature DB >> 21180622

Evidence-based drug treatment in amyotrophic lateral sclerosis and upcoming clinical trials.

Albert C Ludolph1, Sarah Jesse.   

Abstract

Amyotrophic Lateral sclerosis/motor neuron disease is a severe neurodegenerative disease characterized by upper and Lower motor neuron degeneration for which there is no truly effective treatment. Several therapies have shown promise in preclinical models of motor neuron disease; however, most of them failed in human studies, so that the noticeable progress in understanding the cellular mechanisms of motor neuron degeneration has not been matched with the development of therapeutic strategies to prevent disease progression or to extend survival longer than achieved by riluzole. We review treatment development in motor neuron disease and discuss the strengths and limitations of past as well as upcoming clinical trials.

Entities:  

Keywords:  amyotrophic lateral sclerosis; clinical trials; evidence-based therapy

Year:  2009        PMID: 21180622      PMCID: PMC3002601          DOI: 10.1177/1756285609336399

Source DB:  PubMed          Journal:  Ther Adv Neurol Disord        ISSN: 1756-2856            Impact factor:   6.570


  49 in total

1.  Matrix metalloproteinases--a conceptional alternative for disease-modifying strategies in ALS/MND?

Authors:  Albert C Ludolph
Journal:  Exp Neurol       Date:  2006-06-30       Impact factor: 5.330

2.  [Minocycline for the treatment of amyotrophic lateral sclerosis: neuroprotector or neurotoxin? Reflections on another failure of translational medicine].

Authors:  J Gámez
Journal:  Neurologia       Date:  2008-10       Impact factor: 3.109

3.  Intake of polyunsaturated fatty acids and vitamin E reduces the risk of developing amyotrophic lateral sclerosis.

Authors:  J H Veldink; S Kalmijn; G-J Groeneveld; W Wunderink; A Koster; J H M de Vries; J van der Luyt; J H J Wokke; L H Van den Berg
Journal:  J Neurol Neurosurg Psychiatry       Date:  2006-04-28       Impact factor: 10.154

4.  Late-onset motoneuron disease caused by a functionally modified AMPA receptor subunit.

Authors:  Rohini Kuner; Anthony J Groom; Iris Bresink; Hans-Christian Kornau; Vanya Stefovska; Gerald Müller; Bettina Hartmann; Karsten Tschauner; Stefan Waibel; Albert C Ludolph; Chrysanthy Ikonomidou; Peter H Seeburg; Lechoslaw Turski
Journal:  Proc Natl Acad Sci U S A       Date:  2005-04-12       Impact factor: 11.205

5.  Efficient three-drug cocktail for disease induced by mutant superoxide dismutase.

Authors:  Jasna Kriz; Geneviève Gowing; Jean-Pierre Julien
Journal:  Ann Neurol       Date:  2003-04       Impact factor: 10.422

6.  The oral antidiabetic pioglitazone protects from neurodegeneration and amyotrophic lateral sclerosis-like symptoms in superoxide dismutase-G93A transgenic mice.

Authors:  Burkhard Schütz; Jens Reimann; Lucia Dumitrescu-Ozimek; Karin Kappes-Horn; Gary E Landreth; Britta Schürmann; Andreas Zimmer; Michael T Heneka
Journal:  J Neurosci       Date:  2005-08-24       Impact factor: 6.167

7.  Efficacy of minocycline in patients with amyotrophic lateral sclerosis: a phase III randomised trial.

Authors:  Paul H Gordon; Dan H Moore; Robert G Miller; Julaine M Florence; Joseph L Verheijde; Carolyn Doorish; Joan F Hilton; G Mark Spitalny; Robert B MacArthur; Hiroshi Mitsumoto; Hans E Neville; Kevin Boylan; Tahseen Mozaffar; Jerry M Belsh; John Ravits; Richard S Bedlack; Michael C Graves; Leo F McCluskey; Richard J Barohn; Rup Tandan
Journal:  Lancet Neurol       Date:  2007-11-05       Impact factor: 44.182

8.  Treatment with arimoclomol, a coinducer of heat shock proteins, delays disease progression in ALS mice.

Authors:  Dairin Kieran; Bernadett Kalmar; James R T Dick; Joanna Riddoch-Contreras; Geoffrey Burnstock; Linda Greensmith
Journal:  Nat Med       Date:  2004-03-21       Impact factor: 53.440

9.  Minocycline delays disease onset and mortality in a transgenic model of ALS.

Authors:  Ludo Van Den Bosch; Petra Tilkin; Griet Lemmens; Wim Robberecht
Journal:  Neuroreport       Date:  2002-06-12       Impact factor: 1.837

10.  Prognostic modelling of therapeutic interventions in amyotrophic lateral sclerosis.

Authors:  M R Turner; M Bakker; P Sham; C E Shaw; P N Leigh; A Al-Chalabi
Journal:  Amyotroph Lateral Scler Other Motor Neuron Disord       Date:  2002-03
View more
  9 in total

1.  Specific Expression of Glial-Derived Neurotrophic Factor in Muscles as Gene Therapy Strategy for Amyotrophic Lateral Sclerosis.

Authors:  Guillem Mòdol-Caballero; Mireia Herrando-Grabulosa; Belén García-Lareu; Sergi Verdés; Rubén López-Vales; Gemma Pagès; Miguel Chillón; Xavier Navarro; Assumpció Bosch
Journal:  Neurotherapeutics       Date:  2021-03-30       Impact factor: 7.620

2.  EST79232 and EST79376, Two Novel Sigma-1 Receptor Ligands, Exert Neuroprotection on Models of Motoneuron Degeneration.

Authors:  Núria Gaja-Capdevila; Neus Hernández; Sandra Yeste; Raquel F Reinoso; Javier Burgueño; Ana Montero; Manuel Merlos; José M Vela; Mireia Herrando-Grabulosa; Xavier Navarro
Journal:  Int J Mol Sci       Date:  2022-06-16       Impact factor: 6.208

3.  Impact of Limb Phenotype on Tongue Denervation Atrophy, Dysphagia Penetrance, and Survival Time in a Mouse Model of ALS.

Authors:  Marissa Mueller; Rebecca Thompson; Kate L Osman; Ellyn Andel; Chandler A DeJonge; Sophia Kington; Zola Stephenson; Ali Hamad; Filiz Bunyak; Nicole L Nichols; Teresa E Lever
Journal:  Dysphagia       Date:  2022-04-15       Impact factor: 2.733

Review 4.  Potential new complication in drug therapy development for amyotrophic lateral sclerosis.

Authors:  Svitlana Garbuzova-Davis; Avery Thomson; Crupa Kurien; R Douglas Shytle; Paul R Sanberg
Journal:  Expert Rev Neurother       Date:  2016-07-15       Impact factor: 4.618

5.  Metformin treatment has no beneficial effect in a dose-response survival study in the SOD1(G93A) mouse model of ALS and is harmful in female mice.

Authors:  Hannah M Kaneb; Paul S Sharp; Nazanin Rahmani-Kondori; Dominic J Wells
Journal:  PLoS One       Date:  2011-09-01       Impact factor: 3.240

6.  Associative Increases in Amyotrophic Lateral Sclerosis Survival Duration With Non-invasive Ventilation Initiation and Usage Protocols.

Authors:  Nishad Khamankar; Grant Coan; Barry Weaver; Cassie S Mitchell
Journal:  Front Neurol       Date:  2018-07-12       Impact factor: 4.003

7.  Electrophysiologic biomarkers for assessing disease progression and the effect of riluzole in SOD1 G93A ALS mice.

Authors:  Jia Li; Minhee Sung; Seward B Rutkove
Journal:  PLoS One       Date:  2013-06-06       Impact factor: 3.240

8.  Neurotrophic Properties of C-Terminal Domain of the Heavy Chain of Tetanus Toxin on Motor Neuron Disease.

Authors:  Mireia Herrando-Grabulosa; Caty Casas; Kevin Talbot; José Aguilera
Journal:  Toxins (Basel)       Date:  2020-10-21       Impact factor: 4.546

9.  Sigma-1 Receptor is a Pharmacological Target to Promote Neuroprotection in the SOD1G93A ALS Mice.

Authors:  Núria Gaja-Capdevila; Neus Hernández; Xavier Navarro; Mireia Herrando-Grabulosa
Journal:  Front Pharmacol       Date:  2021-12-10       Impact factor: 5.810

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.